Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG-OVV01
- Development stage
- Preclinical
- Lead developer
- Shanghai Rongrui Pharmaceutical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
RG-OVV01 is an investigational, preclinical-stage chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Hangzhou RonGu Biotechnology for the treatment of solid tumors. The therapeutic candidate is engineered using lentiviral gene transfer and incorporates an oncolytic virus (OVV) component to enhance anti-tumor efficacy. The specific molecular targets of the CAR-NK and the oncolytic virus have not been publicly disclosed.
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on RG-OVV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RG-OVV01.